Last reviewed · How we verify
NCT03964324
NO Measurements in Screening for Asthma and OSA, in Patients With Severe Snoring
NA trial testing Fractioned Exhaled Nitrogen Oxide measurements in Snoring in 51 participants. Completed in 31 May 2021.
31 May 2021
Quick facts
| Lead sponsor | Christian von Buchwald |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 51 |
| Start date | 17 September 2019 |
| Primary completion | 31 May 2021 |
| Estimated completion | 31 May 2021 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Fractioned Exhaled Nitrogen Oxide measurements
Conditions studied
- Snoring — all drugs for Snoring →
- Obstructive Sleep Apnea — all drugs for Obstructive Sleep Apnea →
- Asthma — all drugs for Asthma →
- Airway Disease — all drugs for Airway Disease →
Sponsor
Christian von Buchwald — full company profile →
Who can join
18 and older, any sex, with Snoring or Obstructive Sleep Apnea. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In Denmark an estimated 200.000 patients suffer from obstructive sleep apnoea (OSA). The breathing pauses during sleep result in varying degrees of symptoms ranging from none over disturbed sleep to severe daytime sleepiness and cognitive deficits such as reduced short-term memory and difficulty concentrating. In addition, it increases the risk of hypertension, cardiovascular thromboembolic disease and type-2 diabetes as well as causing a 3-6 times increased risk of being involved in traffic accidents. Recent studies suggest that measurement of fractioned exhaled nitrogen oxide (FeNO) from the upper airway may be used as marker for airway inflammation. Studies have demonstrated that inflammation of the airway is present in OSA. In this study the investigators want to see whether FeNO measurements from the upper airway can be used to screen severe snorers for OSA. OSA is rarely diagnosed in patients with chronic rhinosinusitis (CRSwNP) or asthma. The connection between these three inflammatory conditions and the level of FeNO has not previously been investigated but might be clarified in our study. Patients suffering from severe snoring will be offered inclusion. The patients will undergo an ENT examination as well as FeNO testing and testing of lung function. A sleep study will be made as well as they will be asked to fill out questionnaires on sleep quality, nasal symptoms, lung function and their health in general.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Fractional exhaled nitric oxide-a possible biomarker for risk of obstructive sleep apnea in snorers.
Kiaer E, Ravn A, Jennum P, Prætorius C, et al · · 2024 · cited 5× · PMID 37707290 · DOI 10.5664/jcsm.10802
Verify or expand the search:
- PubMed search for NCT03964324
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fractioned Exhaled Nitrogen Oxide measurements
Trials testing the same drug.
- NCT03963648 — NO Measurements in Screening for Asthma and OSA, in Patients With CRSwNP · NA · unknown
Other recruiting trials for Snoring
Currently open trials in the same condition.
- NCT07103941 — IOA Preventing Occlusal Changes With MAD Use · NA · recruiting
- NCT06594627 — Smart Pillows for Enhancing Sleep Quality · NA · recruiting
- NCT06905951 — The Impact of Technology in Obstructive Sleep Apnea Myofunctional Therapy · NA · active not recruiting
- NCT05719779 — Tolerance and Benefits of Mandibular Advanced Device for Snoring and Sleep Apnea in Oropharyngeal Cancer. · NA · recruiting
- NCT03646214 — Improving Sleep Quality During Pregnancy Using an Oral Appliance · NA · recruiting
Other Christian von Buchwald trials
Trials by the same sponsor.
- NCT05045846 — Diagnostic Accuracy of Rapid Antigen Test Based on Anterior Nasal Swab Compared With RT-PCR for SARS-CoV-2 Detection. · completed
- NCT03963648 — NO Measurements in Screening for Asthma and OSA, in Patients With CRSwNP · NA · unknown
- NCT03942380 — Cell-free Tumor DNA in Head and Neck Cancer Patients · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03964324 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Christian von Buchwald
- Last refreshed: 2 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03964324.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing